Answers are grounded in this paper and cite their sources.
Dravet syndrome is a prototypical genetic developmental and epileptic encephalopathy, caused by pathogenic variants in the sodium channel alpha-1 subunit gene (SCN1A) in 95% of individuals. The classic presentation of Dravet syndrome is a baby aged about 6 months, with typical development, who presents with a prolonged febrile generalised tonic-clonic or hemiclonic seizure, and frequent seizures ensue. Individuals with Dravet syndrome usually develop multiple seizure types alongside developmental slowing, and sometimes regression, and a range of morbidities emerge. Dravet syndrome is associated with a poor prognosis and a high risk of mortality. De novo SCN1A pathogenic variants typically cause Dravet syndrome, but parental mosaicism might occur, with implications for reproductive counselling. Early diagnosis is essential to guide prompt, optimal selection of antiseizure medications to control seizures and improve long-term outcomes. Natural history studies are crucial for interpreting the outcomes of trials of novel therapies. Newer antiseizure medications show improved efficacy in controlling seizures, often associated with developmental gains. Pivotal antisense oligonucleotide and genetic therapy trials show promise to transform this devastating disease.
No takes yet. Share an insight, caveat, or question.
Ingrid E. Scheffer (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: